
Molecular Basis of Autosomal Dominant Hypercholesterolemia
Author(s) -
Anouk van der Graaf,
Hans J. Avis,
D. Meeike Kusters,
Maud N. Vissers,
Barbara A. Hutten,
Joep C. Defesche,
Roeland Huijgen,
Sigrid W. Fouchier,
Frits A. Wijburg,
John J.P. Kastelein,
Albert Wiegman
Publication year - 2011
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.110.979450
Subject(s) - medicine , familial hypercholesterolemia , pcsk9 , apolipoprotein b , ldl receptor , endocrinology , population , penetrance , dyslipidemia , phenotype , lipoprotein , genetics , cholesterol , disease , gene , biology , environmental health
Autosomal dominant hypercholesterolemia (ADH) is characterized by elevated low-density lipoprotein cholesterol levels and premature cardiovascular disease. Mutations in the genes encoding for low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin 9 (PCSK9) underlie ADH. Nevertheless, a proportion of individuals who exhibit the ADH phenotype do not carry mutations in any of these 3 genes. Estimates of the percentage of such cases among the ADH phenotype vary widely. We therefore investigated a large pediatric population with an unequivocal ADH phenotype to assess the molecular basis of hereditary hypercholesterolemia and to define the percentage of individuals with unexplained dyslipidemia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom